發(fā)布時間：2018-04-18 15:36

  本文選題：急性冠脈綜合征 + 瑞舒伐他汀　； 參考：《中國藥房》2017年11期

【摘要】：目的:觀察急性冠脈綜合征(ACS)患者接受強化劑量瑞舒伐他汀治療的遠期療效,并探討其可能機制,為臨床診療提供參考。方法:將我院2013年1月-2015年1月臨床治愈后接受瑞舒伐他汀治療的ACS患者102例,按照瑞舒伐他汀劑量的不同分為觀察組和對照組,其中觀察組55例,對照組47例。兩組患者均在同一組醫(yī)師的指導下,在常規(guī)治療的基礎上接受瑞舒伐他汀鈣片治療,觀察組劑量為20 mg,qd,po,對照組為10 mg,qd,po。兩組患者均治療1年。比較兩組患者1年主要心臟事件(MACE)累積發(fā)生率、治療前及治療3個月后血脂水平、血清細胞因子水平及不良反應發(fā)生情況。結果:觀察組患者1年內MACE累積發(fā)生率顯著低于對照組患者,差異有統(tǒng)計學意義(P0.05)。治療后,兩組患者總膽固醇(TC)及低密度脂蛋白膽固醇(LDL-C)水平均較治療前顯著降低,高密度脂蛋白膽固醇(HDL-C)水平較治療前顯著升高,且觀察組LDL-C水平顯著低于對照組,差異均有統(tǒng)計學意義(P0.05)。治療后,兩組患者血清白細胞介素1β(IL-1β)及腫瘤壞死因子α(TNF-α)水平均較治療前顯著降低(P0.05),且觀察組顯著低于對照組,差異有統(tǒng)計學意義(P0.05)。觀察組患者治療后外周血LDL-C與IL-1β、TNF-α均呈現顯著正相關關系,有統(tǒng)計學意義(P0.05)。兩組患者不良反應發(fā)生率比較,差異無統(tǒng)計學意義(P0.05)。結論:強化劑量瑞舒伐他汀治療可顯著改善ACS患者的遠期預后,這可能與其調控脂質代謝及抗炎作用有關。
[Abstract]:Objective: to observe the long-term effect of intensive dose of resuvastatin in patients with acute coronary syndrome (ACS), and to explore its possible mechanism, and to provide reference for clinical diagnosis and treatment.Methods: 102 ACS patients who were cured from January 2013 to January 2015 were divided into observation group (n = 55) and control group (n = 47) according to the dosage of resuvastatin.Under the guidance of the same group of physicians, both patients were treated with rosuvastatin calcium tablets on the basis of routine treatment. The dosage of the observation group was 20 mg / kg QD group and the control group was 10 mg / g QD group.Both groups were treated for 1 year.The cumulative incidence of major cardiac events in one year, serum lipid levels, serum cytokines and adverse reactions were compared between the two groups before and 3 months after treatment.Results: the cumulative incidence of MACE in the observation group was significantly lower than that in the control group (P 0.05).After treatment, the levels of total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) in both groups were significantly lower than those before treatment, and the levels of HDL-C in high density lipoprotein cholesterol (HDL-C) were significantly higher than those before treatment, and the levels of LDL-C in the observation group were significantly lower than those in the control group.The difference was statistically significant (P 0.05).After treatment, the serum levels of IL-1 尾 and TNF- 偽 in the two groups were significantly lower than those before treatment, and the levels in the observation group were significantly lower than those in the control group (P 0.05).There was a significant positive correlation between peripheral blood LDL-C and IL-1 尾 TNF- 偽 after treatment in the observation group (P 0.05).There was no significant difference in the incidence of adverse reactions between the two groups (P 0.05).Conclusion: the long-term prognosis of patients with ACS can be significantly improved by intensive dose of Risuvastatin, which may be related to the regulation of lipid metabolism and anti-inflammatory effects.
【作者單位】： 天津中醫(yī)藥大學第一附屬醫(yī)院急癥部;
【分類號】：R541.4

【參考文獻】

相關期刊論文 前1條

1 胡允兆;黃裕立;吳焱賢;黎文生;楊友;陳盈文;陳玉映;;不同年齡階段冠心病患者危險因素的對比分析[J];實用醫(yī)學雜志;2013年05期

【共引文獻】

相關期刊論文 前10條

1 嚴敏;;血清高敏促甲狀腺激素水平在預測冠狀動脈病變程度中的應用研究[J];醫(yī)藥論壇雜志;2017年06期

2 黃麗;何宗義;李國巖;;氨氯地平、瑞舒伐他汀聯(lián)合非諾貝特治療高血壓合并冠心病的臨床研究[J];海南醫(yī)學;2017年12期

3 龔福漢;劉浙波;夏豪;;經皮冠狀動脈介入術后支架內再狹窄的相關危險因素分析[J];中華實用診斷與治療雜志;2017年05期

4 劉梅;李桂偉;;急性冠脈綜合征患者接受強化劑量瑞舒伐他汀治療的臨床觀察[J];中國藥房;2017年11期

5 張國愷;;中青年冠心病患者平板運動前后血流動力學指標變化分析[J];中國實用醫(yī)藥;2017年09期

6 楊桑杰草;吳軍;李海林;;亞高原地區(qū)冠心病及危險因素的特點[J];甘肅科技縱橫;2017年03期

7 余朝萍;許鋒成;藍亞平;龔厚文;楊靜;龔厚文;黃瑛;尹曉華;張慶;;冠心病患者反應性充血指數與心功能及預后的關系分析[J];四川醫(yī)學;2017年03期

8 徐興偉;林州;吳正春;;姜黃素膠囊治療冠心病心絞痛的療效觀察[J];中國中醫(yī)急癥;2017年01期

9 陳建平;;CT冠狀動脈成像與冠狀動脈造影診斷冠心病的臨床價值對照分析[J];中國CT和MRI雜志;2017年01期

10 張淑波;;長期吸煙史對CHD患者口服阿司匹林二級預防效果的影響[J];西南國防醫(yī)藥;2016年12期

【二級參考文獻】

相關期刊論文 前2條

1 沈衛(wèi)峰;胡大一;;非ST段抬高急性冠狀動脈綜合征診斷和治療指南[J];中華心血管病雜志;2012年05期

2 賈洪順;劉磊;楊建明;全顯躍;;CT冠狀動脈造影在冠心病診斷中的應用價值[J];實用醫(yī)學雜志;2011年02期

，

本文編號：1768984